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A B S T R A C T
Central sensitivity syndrome (CSS) consists of adaptive pathophysiological changes associated with neuroplas-
ticity in some chronic pain disorders. It could be grouped in two main conceptual conditions: one includes those
chronic pain patients without overt structural pathology such as fibromyalgia, and the other subgroup includes
conditions with recognizable structural abnormalities, both somatic (osteoarthritis) and visceral (endometriosis).
In order to understand the role of neuromodulators in CCS we aim to determine whether brain-derived neu-
rotrophic factor (BDNF) and S100B are associated to specific chronic pain disorders. Serum BDNF and S100B
were measured in chronic pain women with different diagnosis: 88 with osteoarthritis, 36 with endometriosis,
117 with fibromyalgia, 33 with chronic tension type headache and in 41 healthy controls. ANCOVA analysis
followed by heteroscedasticity-consistent covariance matrix was performed to evaluate BDNF and S100B levels,
adjusted for depression severity, pain levels and use of analgesics according different pathologies. Serum BDNF
concentrations were higher and not different in patients with fibromyalgia and headache, the CSS group without
structural pathology. In contrast, the concentrations of S100B were higher in patients with osteoarthritis and
endometriosis, in comparison to controls, fibromyalgia and tensional headache patients. This study supports the
hypothesis that BDNF and S100B neuromodulators present different serum levels according to the background
disease associated to the chronic pain. These have the potential to be studied as markers of active disease or
treatment evolution.
1. Introduction
Chronic pain represents one of the main causes of incapacity and
suffering in adult life. Central sensitivity syndrome (CSS) consists of
adaptive pathophysiological changes mediated by the central nervous
system (CNS) associated with neuroplasticity in some chronic pain
disorders [1]. It depicts an enlargement of the neurons and circuits
functions of the nociceptive pathway caused by increased excitability
and synaptic efficacy, as well as the reduction of inhibition. It includes
symptoms as psychological distress, sleeping disorders, fatigue, pain,
allodynia, hyperalgesia, expansion of the receptive field, prolonged
electrophysiological discharge, and an after-stimulus unpleasant quality
of the pain [1,2].
The CSS could be grouped in two main conceptual conditions: one
includes those without overt structural pathology, such as fibromyalgia,
myofascial pain syndrome, and chronic tensional type headache
(CTTH). The other subgroup includes conditions with recognizable
structural abnormalities, both somatic (osteoarthritis) and visceral
(endometriosis) [3,4]. Identifying the chronic pain patients with CSS
helps to design the treatment, to agree to the prognostic and to get the
patients and their families involved.
To delineate the profile of central sensitization conditions, some
objective testing can be done, including functional magnetic resonance
and cerebral evoked potential [5]. Also, the physiology of CSS involves
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activation of several neurotransmitters and neuromodulators acting
along pain pathways which could be used in a more accessible manner
(blood sampling) to help the CSS identification [5].
Brain-derived neurotrophic factor (BDNF) is a remarkable marker
and modulator of neuronal activity and N-methyl-D-aspartate (NMDA)
receptor dependent neuronal plasticity in pain transmission pathways
[6]. In animals, when neutralizing BDNF by anti-BDNF antibody, me-
chanical allodynia [7] and thermal hyperalgesia were relieved [8]. In
humans, our group has demonstrated higher levels of BDNF in patients
with fibromyalgia, headache, and myofascial pain [3]. Furthermore,
BDNF serum levels were significantly correlated with decreased in-
hibitory system as assessed by conditioned pain modulation [9] and
with the reduction of pressure pain thresholds in fibromyalgia [10].
S100B is a calcium-binding protein associated to the upregulation of
other mediators expression such as Interleukin 1-Beta and Tumor
Necrosis Factor (TNF) and to the activation of the nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-kB) in microglia and as-
trocytes [11]. In animal models, S100B was associated to hyperalgesia
[12], and in humans with fibromyalgia; it was associated to reduced
pain thresholds in pressure pain testing [10].
Considering the common mechanisms shared by some diseases with
peripheral and central mechanisms associated to CSS, it is reasonable to
hypothesize that BDNF and S100B serum levels may have different
courses according to the disease associated to chronic pain and central
sensitization diagnosis.
2. Methods
2.1. Design overview, settings, and participants
This is a cross-sectional study in which the final sample data was
pooled from five clinical trials from September 2012 to March 2013 at
the Pain and Neuromodulation Research Group of Hospital de Clínicas
de Porto Alegre (HCPA). All the trials were approved by the HCPA
Ethics Committee and the informed written consent was obtained from
all subjects. The studies involved women with chronic pain conditions
such as fibromyalgia (NCT02041455; NCT01804097), osteoarthritis
(NCT01747070; NCT01855958), endometriosis (NCT02161302) and
CTTH (NCT01954277). Details of the inclusion of each study can be
seen in Fig. S1 (Supplementary material). Patients were recruited from
the institutional chronic pain clinic or from other clinic units and media
advertisement. Patients who didn’t understand Brazilian Portuguese or
who presented cancer, uterine fibroids, ovarian cysts, inflammatory
pelvic disease, pregnancy, and kidney or hepatic insufficiency were
excluded. Each clinical trial had strict inclusion criteria and the diag-
noses were confirmed by a doctor with more than 15 years of experi-
ence in chronic pain. The diagnosis was determined by clinical com-
plaints and physical examination, as well as current and past
medication, medical and psychiatric care. Within it were patients who
had experienced pain both scored in the visual analog scale (VAS)
as> 40mm (i.e., moderate or severe pain – which was an inclusion
criteria shared by the clinical trials used) [13] and that lasted> 3
months, associated with functional disability. This was assessed in-
quiring whether the disease had troubled patients, in the last 3 months,
with work; enjoyable activities; responsibilities at home; relationships;
personal goals and thinking clearly. For inclusion, patients had to have
at least one positive answer.
Trials details criteria are summarized as follows:
1 Osteoarthritis: was confirmed by clinical and radiographic criteria
of the American College of Rheumatology [14] and by the Western
Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
[15]. Patients with a disability score on the WOMAC≥ 21 were
included.
2 Fibromyalgia: diagnosis was confirmed by the 2010 American
College of Rheumatology criteria [16].
3 Endometriosis: was confirmed by laparoscopy associated with pelvic
pain and/or dyspareunia of moderate to severe intensity (pain
level > 4 on the VAS) [13] lasting > 6 months.
4 CTTH: diagnosis was based on criteria from the International
Classification of Headache Disorders [17]. Participants had to ex-
perience headaches with following symptoms for more than 180
days in the last year: pain lasting hours to days; bilateral, pressing or
tightening quality; mild or moderate intensity; and not aggravated
by routine physical activities. A headache specialist confirmed the
diagnosis.
5 Volunteers: Pain-free control volunteers were invited from the
community using media advertisement. Painful condition; analge-
sics or corticosteroids use; rheumatologic, psychiatric, or neurolo-
gical disorder; alcohol abuse or psychotropic substances use during
the 6 months previous to the screening; or medications with effects
on the CNS use were exclusion criteria.
2.2. Serum neuroplasticity mediators’ concentration
Biological samples were collected early in the morning. All the
material was obtained in vacutainer tubes without anticoagulant and
centrifuged for 10min at 4500 rpm at 4 °C. The serum was frozen at
−80 °C until further analyses. Serum mediators’ concentrations were
determined by using BDNF (Millipore, Missouri, USA, catalogue
#CYT306, kit’s lower detection limit= 7.8 pg/mL) and S100B
(Millipore, Missouri, USA, catalogue #EZHS100B-33 K, kit's lower de-
tection limit= 2.7 pg/mL) enzyme-linked immunosorbent assay kits
(ELISA), according to the manufacturers’ instructions.
2.3. Potential confounding variables
All psychological tests used had been validated for the Brazilian
population. The patients’ depressive symptoms were assessed using the
Hamilton Depression Rating Scale (HDRS) [18] and were classified as
mild if ranging from 11 to 17; and moderate to severe if ≥ 18. OA
patients’ answered the Beck Depression Inventory (BDI) and the de-
pressive symptoms were classified as mild if≤ 18 and as moderate to
severe if > 18 [19]. The number of doses used weekly within the last 3
months determined analgesic use.
2.4. Statistical analyses
Comparisons between continuous variables were performed using
either ANOVA or Kruskal–Wallis tests according to the variables’ dis-
tribution. To evaluate the supposition of ANOVA model we proceed to
the residual analysis. Categorical variables were compared using the
Chi-square or Fisher’s exact test. ANCOVA models were adjusted for
variables S100B and BDNF, aiming to identify significant difference
between their means according the presence or absence of structural
pathology.
Covariates that could interfere in these results were included in the
model: pain severity, age, degree of depressive symptoms and use of
psychotropic medications. Also another ANCOVA model was used to
deeply explore the differences between the biomarkers’ levels in each
disease. The covariates were checked for their multicollinearity. The
model was adjusted to deal with heteroscedasticity through the het-
eroscedasticity-consistent covariance matrix [20]. The alpha level was set
at 0.05. The data were analyzed using SAS Studio 9.4.
3. Results
A sample of 315 patients was allocated from six different studies
conducted by the same research group. Three hundred eighty-two pa-
tients were excluded because they did not meet the inclusion criteria
(VAS < 40mm). According to their underlying pathologies, chronic
pain patients were divided into two groups considering the CSS with
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persistent somatic/visceral nociceptive input (the presence of structural
lesion) or its absence. Patients with osteoarthritis (n= 88) and en-
dometriosis (n= 36) were included in the group with structural pa-
thology, and patients with fibromyalgia (n= 117) and tensional
headache (n=33) were grouped as absent structural lesion. For the
non-patient comparison sample, 41 female volunteers were screened
(Fig. S1 – Supplementary material).
Groups were classified with respect to age, body mass index, pain
severity, depressive symptoms, and use of pain medications (Table S1 -
Supplementary material). The distribution of data value of BDNF and
S100B according the different pathologies was illustrated by the box
plot (Fig. 1).
Table 1 shows the result of serum BDNF and S100B concentration
values according presence or absence of structural pathology, con-
trolled for confounding factors such as age, degree of pain, depression
or analgesic consumption. The kind of disease had a significant effect
on BDNF, (F2,303= 19.21; p < 0.01) and on S100B levels
(F2,293= 11.70, p < 0.01).
Table 2 shows the result of ANCOVA model with heteroscedasticity-
consistent covariance matrix used to compare the result of BDNF and
S100B serum concentrations according to the different pathologies,
controlled for confounding factors. The kind of chronic pain condition
had a significant effect on BDNF, F4,301= 9.59; p < 0.01) and on
S100B levels, F2,293= 8.01; p < 0.01. Table S2 (Supplementary ma-
terial) shows the complete result of ANCOVA analysis.
BDNF was higher and not different in patients with fibromyalgia
and headache, the CSS group without structural pathology, compared
to osteoarthritis, endometriosis and healthy groups. In contrast, the
concentrations of S100B were higher in patients with osteoarthritis and
endometriosis, the CSS group with structural pathology, in comparison
to controls, fibromyalgia and tensional headache patients.
4. Discussion
This study supports the hypothesis that BDNF and S100B neuro-
modulators present different serum levels according to the background
disease associated to the chronic pain.
Our main find is the confirmation of BDNF increase in patients with
CSS without structural pathology, as in fibromyalgia and chronic ten-
sion headaches. In these groups, BDNF serum level - controlled to other
factors such as depression, pain levels, and the use analgesics - was
significantly greater than in women who are healthy or affected by
diseases with the presence of structural pathology, namely with per-
sistent nociceptive stimulus.
Both fibromyalgia and chronic tension headache share common
sensitization mechanisms as amplification of afferent signals and in-
adequate descendent inhibitory control [21] associated to a psycholo-
gical chronic stress. In CTTH it has been demonstrated that continuous
nociceptive input from pericranial myofascial tissues may induce su-
praspinal sensitization and thereby the chronification of headaches
[22]. The psychological stress may cause a prolonged increase of
muscle tone via the limbic system and also potentiate pain facilitation
from the brain stem to the spinal dorsal horn [23].
In fibromyalgia there is a scarce evidence of structural pathology,
that is, a non-nociceptive component related to the phenomenon of
central sensitization. It is considered a disorder of the nociceptive
processing with immunity system deregulation and inflammation [24].
In addition, affective changes and mood disorders are typically ob-
served in both diseases. BDNF orchestrates mechanisms of neuronal
plasticity and survival, holding the capacity to sensitize peripheral
nociceptors and increasing excitability of second order neurons. It has
already been shown that intact BDNF crosses the blood-brain-barrier by
a high-capacity, saturable transport system [25]. Even though its serum
levels in humans are affected by time of day of blood withdrawal, age,
sex, urbanicity, smoking status and alcohol use, the effect sizes of these
variables are generally small [26].
In pain processes, BDNF levels alter the descending nociceptive in-
hibition towards nociceptive facilitation in the brain. It is also an im-
portant facilitator of long-term potentiation (LTP), especially in regions
involved in learning and memory, which may be related to the gen-
eration of pain memories in chronic pain patients [27]. Giving this
multiplicity of actions, our results corroborate that pain associated to
central sensitivity and to central nervous dysfunction has a biological
substrate. In a previous study of our group we observed increased levels
of BDNF and TNF-α in patients with CSS without structural pathology
[3]. In addition, we demonstrated that serum BDNF may be involved in
processes that mediate the disinhibition of motor cortex excitability,
Fig. 1. Box plot of neuromodulators informing the spread and variability of
BDNF (A) and S100B (B) data by multiple categories of diseases. The con-
centration of BDNF and S100B are in pg/mL. BDNF=brain-derived neuro-
trophic factor. CTH= chronic tension headache. ENDO=endometriosis.
FM= fibromyalgia. OA=osteoarthritis.
Table 1
Serum neuroplasticity mediators’ concentration according presence or absence








BDNF levels (pg/mL) 38.48a 24.22b 23.13b < 0.01
S100B levels (pg/mL) 18.22a 22.64b 14.34a < 0.01
Differences were tested using ANCOVA. The variables included in the model
were: moderate/severe depression, age, pain scale and use of pain medication.
The groups sharing a letter are not significantly different. The model was ad-
justed to deal with heteroscedasticity through the heteroscedasticity-consistent
covariance matrix.
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along with the function of the descending inhibitory pain modulation
system, independently of the physiopathology mechanism of muscu-
loskeletal pain syndromes [9]. In patients with CTTH BDNF levels
changed after pain modulation provided by electroacupuncture an-
algesia versus sham stimulation [28].
These findings are important in narrowing the gap between the
patient's perception of their illness and their health care professional.
Patients with ‘unexplained’ chronic musculoskeletal pain who are
misinformed about pain, have low adherence for active treatments
[29]. The objective serum biological marker could help reconceptualise
pain before initiating the treatment. Also, this approach can prevent the
patient from suffering about the scientific background of their pain. The
early CSS diagnosis can help reduce the staff and resources invested in
misleading and stressful tests, enabling efforts to be directed toward
safer and effective interventions (e.g., psychotherapy, physical activity)
[3].
Distinctively, while BDNF was predominantly higher in chronic pain
patients without structural pathology, S100B levels were pre-
dominantly elevated in patients with CSS with structural pathology,
represented by osteoarthritis and endometriosis. Osteoarthritis carries a
strong nociceptive joint component associated to central sensitization
in advanced stages. This central sensitization was demonstrated in a
cross-sectional study on women with osteoarthritis in which the change
in cortical plasticity was associated with less intracortical inhibition
[30]. Several key mediators are particularly involved in the generation
and maintenance of osteoarthritis pain, such as nerve growth factor
(NGF), and cytokines [31].
Glia is thought to be involved in the propagation and modulation of
acute and chronic painful stimuli, as well as in the neurotransmission
and plastic changes. S100B protein is released from the glia after neu-
ronal damage, for instance, after a head injury [12] or cardiopulmonary
bypass. Furthermore, in a recent study with patients submitted to bi-
lateral total knee arthroplasty, liquoric S100B decreased significantly
one week after the operation, compared to the basal value [32].
Patients with endometriosis also have shown elevated basal levels of
S100B in our sample. Endometrial lesions give rise to different types of
pain, including visceral and myofascial nociception. Visceral nocicep-
tion and peripheral sensitization are secondary to the direct innervation
of endometrial injuries, but over time central sensitization creates a
process for pain sustention that is independent of the initial pathology.
Besides, the viscerosomatic convergence provides the means for pain
referral to somatic structures and induces the muscle spasm reflex and
the eventual formation of myofascial trigger points too. These trigger
points, in turn, may serve as an extra source of nociceptive input, be-
coming a key component of chronic pelvic pain [33]. As far as we know,
this is the first exploratory study that has shown increased S100B levels
in women with moderate to severe chronic pelvic pain. Giving the
complex pain physiopathology associated to endometriosis, it is rea-
sonable to consider S100B as promising biomarker.
Our results should be interpreted in light of some limitations. First,
neuroplasticity mediators are not specific for CSS, once these have
demonstrated association in different scenarios other than pain-like
mood or psychiatric disorders, inflammation, trauma, and even phy-
sical exercises [34]. BDNF and S100B could also be influenced by both
pain severity and depression symptoms. These two factors differed
between our samples and to address the potential confounding effect we
included them as covariates in our analysis. Second, the division of CSS
in absence or presence of structural pathology may be suboptimal.
Granted the complexity of each syndrome and the presence of multiple
mechanisms that could contribute to the final perception of pain, an
approach to design the signature of each disease could be considered.
Third, our sample is strictly made of females and the results related to
BDNF could not be extrapolated to males. In an experimental acute pain
model in volunteers, it was demonstrated that gender interferes in
BDNF levels [35]. Also, the osteoarthritis group had significantly older
age compared to other pathologies. Finally the study's cross-sectional
nature allows associations and not any causality inference, which re-
quires future investigations.
5. Conclusions
Findings from this study have shown increased BDNF levels in
chronic pain patients with CSS in the absence of tissue injury.
Otherwise, S100B had predominantly increased levels in chronic pain
patients with tissue injury. Taking into consideration the overlapping
symptoms and pathophysiological findings in some conditions, these
biomarkers could be used individually as an objective profile validation
of the CSS. Also, they have the potential to be studied as markers of
either the active disease or treatment evolution.
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Table 2
Serum neuroplasticity mediators’ concentration according to different conditions. Values are expressed in pg/mL.
Neuroplasticity mediators Pain-free controls (n= 17) Osteoarthritis (n= 86) Endometriosis (n=36) Fibromyalgia (n= 79) Headache (n= 33) p
BDNF levels (pg/mL) 22.85b 24.85b 23.71b 38,60a 37.22a < 0.01
S100B levels (pg/mL) 11,23a 23,99b 20,27b 19,40a 14,82a < 0.01
Differences were tested using ANCOVA. The variables included in the model were: moderate/severe depression, age, pain scale and use of pain medication. The
groups sharing a letter are not significantly different. The model was adjusted to deal with heteroscedasticity through the heteroscedasticity-consistent covariance
matrix.
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